- Home
- DRMA vs CYCC Comparison
DRMA vs CYCC Comparison
Compare DRMA & CYCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRMA
- CYCC
- Stock Information
- Founded
- DRMA 2014
- CYCC 1992
- Country
- DRMA United States
- CYCC United States
- Employees
- DRMA N/A
- CYCC N/A
- Industry
- DRMA Biotechnology: Pharmaceutical Preparations
- CYCC Biotechnology: Pharmaceutical Preparations
- Sector
- DRMA Health Care
- CYCC Health Care
- Exchange
- DRMA Nasdaq
- CYCC Nasdaq
- Market Cap
- DRMA 1.7M
- CYCC 1.8M
- IPO Year
- DRMA 2021
- CYCC N/A
- Fundamental
- Price
- DRMA $1.12
- CYCC $0.37
- Analyst Decision
- DRMA Strong Buy
- CYCC Buy
- Analyst Count
- DRMA 1
- CYCC 2
- Target Price
- DRMA $6.00
- CYCC $11.00
- AVG Volume (30 Days)
- DRMA 85.2K
- CYCC 3.7M
- Earning Date
- DRMA 11-13-2024
- CYCC 11-12-2024
- Dividend Yield
- DRMA N/A
- CYCC N/A
- EPS Growth
- DRMA N/A
- CYCC N/A
- EPS
- DRMA N/A
- CYCC N/A
- Revenue
- DRMA N/A
- CYCC $74,000.00
- Revenue This Year
- DRMA N/A
- CYCC N/A
- Revenue Next Year
- DRMA N/A
- CYCC $16.28
- P/E Ratio
- DRMA N/A
- CYCC N/A
- Revenue Growth
- DRMA N/A
- CYCC N/A
- 52 Week Low
- DRMA $1.11
- CYCC $0.35
- 52 Week High
- DRMA $13.35
- CYCC $6.00
- Technical
- Relative Strength Index (RSI)
- DRMA 34.78
- CYCC 30.41
- Support Level
- DRMA $1.22
- CYCC $0.37
- Resistance Level
- DRMA $1.54
- CYCC $0.52
- Average True Range (ATR)
- DRMA 0.12
- CYCC 0.08
- MACD
- DRMA -0.01
- CYCC -0.01
- Stochastic Oscillator
- DRMA 2.35
- CYCC 6.59
About DRMA Dermata Therapeutics Inc.
Dermata Therapeutics Inc is a clinical-stage medical dermatology company focused on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. Its two product candidates, DMT310 and DMT410, incorporate its proprietary, multifaceted, Spongilla technology to topically treat a variety of dermatological conditions. Its Spongilla technology platform will enable to develop and formulate singular and combination products that are able to target topical delivery of chemical compounds into the dermis for maximum treatment effect for a variety of inflammatory skin diseases.
About CYCC Cyclacel Pharmaceuticals Inc.
Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors, and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib, Sapacitabine, and plogosertib.